Phibro Animal Health

Phibro Animal Health Corp. engages in the manufacture and supply of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops and markets antibacterial, nutritional specialty products, and vaccines. The Mineral Nutrition segment consists of the formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment produces specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

PAHC reports Q3 sales growth, addresses challenges and opportunities

PAHC's Q3 2023 earnings call highlighted strong sales growth in the Animal Health segment, while facing challenges in the Mineral Nutrition segment. The company reiterated its full-year guidance and discussed various opportunities for growth and expansion.

Phibro Animal Health reports Q2 growth, adjusts guidance for 2023

Phibro Animal Health (PAHC) showed overall growth in net sales and adjusted EBITDA despite challenges in certain regions and segments.
The company remains focused on its full-year guidance but adjusted GAAP expectations due to environmental factors.
Strategic investments and market opportunities present avenues for future growth and performance improvement.

Phibro Animal Health reports strong Q3 sales growth and margin improvement

Phibro Animal Health Corporation demonstrated robust sales growth and margin improvement in the Animal Health segment, while facing challenges related to negative free cash flow. Despite this, the company remains optimistic about meeting its full-year guidance and sees opportunities for growth through market expansion and operational enhancements.

Phibro Animal Health reports strong FY 2023 performance and projects continued growth in Animal Health segment

Phibro Animal Health delivered solid financial performance in FY 2023, with a strong outlook for FY 2024 driven by growth in the Animal Health segment.
Strategic investments in vaccines and companion animals position the company for continued expansion and margin maintenance amidst challenges.
Efforts to enhance operational efficiency and cash flow generation underscore a commitment to sustainable growth and financial strength.
Anticipated top and bottom-line growth, along with market stability, signal a positive trajectory for Phibro Animal Health in the upcoming fiscal year.

Phibro Animal Health reports mixed Q1 results amid market challenges

Phibro Animal Health's Q1 2024 performance was marked by growth in the Animal Health segment but challenges in other segments.
Efforts to manage working capital effectively and maintain a stable financial position are key strengths.
However, declines in adjusted EBITDA, revenue, and margins present hurdles that require strategic solutions.
Opportunities for growth lie in addressing challenges across segments and exploring innovative market strategies.

Phibro Animal Health reports Q2 growth, affirms guidance amid challenges

Phibro Animal Health's Q2 2024 performance reflects solid growth in net sales driven by the Animal Health segment, despite challenges in other segments.
The company's ability to manage operational challenges in Israel and maintain guidance reaffirm confidence in its strategic direction and resilience.
With positive demand trends and a new CFO onboard, Phibro Animal Health is poised to leverage opportunities for growth and operational excellence.

Phibro Animal Health reports robust Q3 performance and strategic acquisitions

Phibro Animal Health (PAHC) delivered a strong Q3 performance with notable growth in total company and Animal Health sales, supported by positive financial metrics and strategic acquisitions.
While facing integration challenges and competitive pressures, the company's strengths in market performance, financial health, and strategic guidance position it well for future growth.
Opportunities in product expansion, market diversification, and innovation present avenues for sustained growth and market leadership in the animal health industry.

Phibro Animal Health posts strong Q4 results, eyes Zoetis acquisition

Phibro Animal Health (PAHC) delivered robust financial results in Q4 2024, driven by growth in key segments and operational improvements.
The pending Zoetis MFA acquisition and successful refinancing demonstrate Phibro's strategic focus on expansion and financial strength.
While challenges in integration and regulatory approvals exist, Phibro is well-positioned to capitalize on opportunities for market expansion and sustained growth.
Investors can look forward to Phibro's continued performance and value creation as it navigates industry dynamics and executes on its strategic initiatives.

Phibro Animal Health reports stellar Q1 results and eyes growth

Phibro Animal Health delivered impressive Q1 2025 results, showcasing robust financial growth and strategic acquisitions.
While facing challenges such as margin concerns and project discontinuations, the company remains optimistic about its future prospects.
By capitalizing on opportunities in the acquired portfolio and focusing on operational excellence, Phibro aims to sustain its growth trajectory and drive shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Phibro Animal Health Corp. engages in the development, manufacture, and marketing of animal health and mineral nutrition products. It operates through the following segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment develops and markets medicated feed additives, nutritional specialty products, and vaccines. The Mineral Nutrition segment includes formulations and concentrations of trace minerals such as zinc, manganese, copper, iron, and compounds. The Performance Products segment produces specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company was founded on May 11, 1946 and is headquartered in Teaneck, NJ.

Phibro (PAHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Phibro (PAHC) Beat Estimates Again in Its Next Earnings Report?

Phibro's (PAHC) Animal Health business, supported by the flourishing Vaccine product line, drives optimism for future growth. However, macroeconomic impacts are a concern.

Is Phibro (PAHC) Stock Worth Retaining in Your Portfolio Now?

Phibro (PAHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Phibro (PAHC) Upgraded to Strong Buy: What Does It Mean for the Stock?

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) proudly announces its third annual Environmental, Social and Governance (ESG) Report, highlighting 2023 achievements. At Phibro, the connections between people, animals and the planet drive us to optimize animal health and nutrition for better lives and a sustainable world. “Phibro's business segments naturally align with today's ESG and corporate responsibility mindset,” said Jack Bendheim, President, CEO and Chair.

Phibro Animal Health Corporation Releases Third Annual ESG Report: Connections that Advance Animal Health, Nutrition and Sustainability

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Stifel Annual Dental and Animal Health (Jaws & Paws) Conference. Chief Financial Officer, Glenn David along with Larry Miller, Chief Operating Officer and EVP Corporate Strategy, Daniel Bendheim will address financial analysts and investors on Wednesday, May 29, 2024, at 10:20 AM ET at the St. Regis New York. The live audio presentation will be available on the Phibro A.

Phibro Animal Health Corporation to Participate in Stifel Dental and Animal Health (Jaws & Paws) Conference

Evaluate Phibro's (PAHC) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Interpreting Phibro (PAHC) International Revenue Trends

Phibro Animal Health Corporation (NASDAQ:PAHC ) Q3 2024 Earnings Conference Call May 9, 2024 9:00 AM ET Company Participants Glenn David - Chief Financial Officer Jack Bendheim - Chairman, President & Chief Executive Officer Daniel Bendheim - Director & Executive Vice President, Corporate Strategy Larry Miller - Chief Operating Officer Conference Call Participants Erin Wright - Morgan Stanley Navann Ty - BNP Paribas Balaji Prasad - Barclays Operator Hello, and thank you for standing by. My name is Regina, and I will be your conference operator today.

Phibro Animal Health Corporation (PAHC) Q3 2024 Earnings Call Transcript

Phibro's (PAHC) impressive fiscal 2024 third-quarter performance continues to be driven by the Animal Health segment.

Phibro (PAHC) Q3 Earnings and Revenues Beat, Gross Margin Down

Although the revenue and EPS for Phibro (PAHC) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Phibro (PAHC) Reports Q3 Earnings: What Key Metrics Have to Say

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its third quarter ended March 31, 2024, and its updated financial guidance for the year ending June 30, 2024. Highlights for the three months ended March 31, 2024 (compared to the three months ended March 31, 2023) Net sales of $263.2 million, an increase of $17.6 million, or 7% Net income of $8.4 million, a decrease of $1.6 million Diluted earnings p.

Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance

Get a deeper insight into the potential performance of Phibro (PAHC) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Unlocking Q3 Potential of Phibro (PAHC): Exploring Wall Street Estimates for Key Metrics

Phibro (PAHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Phibro (PAHC) Moves 31.8% Higher: Will This Strength Last?

Zoetis

PARSIPPANY, N.J. & TEANECK, N.J.--(BUSINESS WIRE)---- $PAHC #animalhealth--Zoetis Inc. (NYSE:ZTS) and Phibro Animal Health Corporation (Nasdaq: PAHC) today announced that they have entered into a definitive agreement where Phibro Animal Health will acquire Zoetis' medicated feed additive (MFA) product portfolio, certain water soluble products and related assets for $350 million, subject to customary closing adjustments. This transaction is expected to be complete in the second half of calendar year 2024. Both Zoetis a.

Zoetis to Sell Medicated Feed Additive Portfolio to Phibro Animal Health

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its third quarter financial results on Wednesday, May 8, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, May 9, 2024, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-202.

Phibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Results

Investors are optimistic about Phibro (PAHC), led by the introduction of new products and upbeat guidance.

Phibro Stock (PAHC) Rises 7% YTD: Will the Run Continue?

Phibro's (PAHC) diversified offerings and prospering vaccine business buoy optimism for investors.

Here's Why Investors Should Buy Phibro (PAHC) Stock Now

Phibro (PAHC) reported earnings 30 days ago. What's next for the stock?

Why Is Phibro (PAHC) Up 12.7% Since Last Earnings Report?

Phibro (PAHC) is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies.

Phibro (PAHC) Appears Well Poised on Launches, Vaccine Sales

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Phibro Animal Health (PAHC) a Great Value Stock Right Now?

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Barclays Global Healthcare Conference. Chief Financial Officer, Glenn David along with Chief Operating Officer, Larry Miller will address financial analysts and investors on Tuesday, March 12, 2024, at 4:35 PM ET at the Loews Miami Beach Hotel. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investo.

Phibro Animal Health Corporation to Participate in Barclays Global Healthcare Conference

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) announced today it will participate in the Bank of America 2024 Virtual Animal Health Summit. Chief Financial Officer, Glenn David along with EVP Corporate Strategy, Dani Bendheim will address financial analysts and investors on Thursday, February 29, 2024, at 10:00 AM ET. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A.

Phibro Animal Health Corporation to Participate in Bank of America 2024 Animal Health Summit

Phibro (PAHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Phibro (PAHC) a New Buy Stock

Phibro Animal Health Corporation (PAHC) Q2 2024 Earnings Call Transcript

Phibro's (PAHC) fiscal 2024 second-quarter results reflect the strong performance of the Animal Health segment.

Phibro (PAHC) Q2 Earnings and Revenues Top, Margins Down

Although the revenue and EPS for Phibro (PAHC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

News for Phibro Animal Health Stock (PAHC)